Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that a...
34175 Ardenwood Boulevard
Fremont, CA 94555
Founded in 2007
Ardelyx, Inc. Appoints Jeremy S. Caldwell as Executive Vice President and Chief Scientific Officer
Dec 1 14
Ardelyx, Inc. announced the appointment of Jeremy S. Caldwell, Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Caldwell brings a wealth of experience in drug discovery and development at several major pharmaceutical companies and in the biotechnology industry as an entrepreneur, having most recently served as Entrepreneur-in-Residence at Third Rock Ventures.
Ardelyx, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 6 14
Ardelyx, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's total revenue was $7,598,000 compared to $6,593,000 a year ago. Income from operations was $81,000 compared to loss from operations of $886,000 a year ago. Income before provision for income taxes was $74,000 compared to loss before provision for income taxes of $899,000 a year ago. Net income and comprehensive income was $74,000 compared to net loss and comprehensive loss of $934,000 a year ago. The increase in net income was primarily driven by the increase in recognized licensing revenue related to milestone payments in accordance with the Company's agreement with AstraZeneca partially offset by expenses related to being a public company following the Company's June 2014 IPO and increased R&D expenses. Net income attributable to common stockholders - Diluted was $74,000 compared to loss attributable to common stockholders of $934,000 a year ago.
For the nine months, the company's total revenue was $25,284,000 compared to $5,967,000 a year ago. Income from operations was $2,369,000 compared to loss from operations of $2,147,000 a year ago. Income before provision for income taxes was $757,000 compared to loss before provision for income taxes of $2,189,000 a year ago. Net income and comprehensive income was $757,000 compared to net loss and comprehensive loss of $2,295,000 a year ago.
Ardelyx, Inc. to Report Q3, 2014 Results on Nov 06, 2014
Oct 30 14
Ardelyx, Inc. announced that they will report Q3, 2014 results on Nov 06, 2014